SK82002A3 - Use of the escitalopram and pharmaceutically acceptable salt thereof - Google Patents
Use of the escitalopram and pharmaceutically acceptable salt thereof Download PDFInfo
- Publication number
- SK82002A3 SK82002A3 SK8-2002A SK82002A SK82002A3 SK 82002 A3 SK82002 A3 SK 82002A3 SK 82002 A SK82002 A SK 82002A SK 82002 A3 SK82002 A3 SK 82002A3
- Authority
- SK
- Slovakia
- Prior art keywords
- medicament
- treatment
- test
- use according
- escitalopram
- Prior art date
Links
- WSEQXVZVJXJVFP-FQEVSTJZSA-N escitalopram Chemical compound C1([C@]2(C3=CC=C(C=C3CO2)C#N)CCCN(C)C)=CC=C(F)C=C1 WSEQXVZVJXJVFP-FQEVSTJZSA-N 0.000 title claims abstract description 17
- 229960004341 escitalopram Drugs 0.000 title claims abstract description 16
- 150000003839 salts Chemical class 0.000 title claims abstract description 11
- 239000003814 drug Substances 0.000 claims abstract description 19
- 206010041250 Social phobia Diseases 0.000 claims abstract description 8
- 208000019906 panic disease Diseases 0.000 claims description 20
- 206010033664 Panic attack Diseases 0.000 claims description 14
- 208000019901 Anxiety disease Diseases 0.000 claims description 9
- 206010029333 Neurosis Diseases 0.000 claims description 8
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 claims description 8
- 208000015238 neurotic disease Diseases 0.000 claims description 8
- 206010034912 Phobia Diseases 0.000 claims description 5
- 239000004480 active ingredient Substances 0.000 claims description 4
- 208000028173 post-traumatic stress disease Diseases 0.000 claims description 4
- 201000001716 specific phobia Diseases 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 abstract description 2
- 238000012360 testing method Methods 0.000 description 40
- 241000700159 Rattus Species 0.000 description 14
- 230000000694 effects Effects 0.000 description 13
- 230000035939 shock Effects 0.000 description 10
- WSEQXVZVJXJVFP-HXUWFJFHSA-N (R)-citalopram Chemical compound C1([C@@]2(C3=CC=C(C=C3CO2)C#N)CCCN(C)C)=CC=C(F)C=C1 WSEQXVZVJXJVFP-HXUWFJFHSA-N 0.000 description 8
- 150000001875 compounds Chemical class 0.000 description 8
- 229960001653 citalopram Drugs 0.000 description 7
- 206010010904 Convulsion Diseases 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 5
- 229920005372 Plexiglas® Polymers 0.000 description 5
- 230000000949 anxiolytic effect Effects 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 206010036067 polydipsia Diseases 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 230000001430 anti-depressive effect Effects 0.000 description 4
- 239000000935 antidepressant agent Substances 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 208000008811 Agoraphobia Diseases 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 230000036506 anxiety Effects 0.000 description 3
- 239000002249 anxiolytic agent Substances 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 230000002045 lasting effect Effects 0.000 description 3
- 238000005192 partition Methods 0.000 description 3
- 239000008188 pellet Substances 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 238000002604 ultrasonography Methods 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 229940005513 antidepressants Drugs 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- KTGRHKOEFSJQNS-BDQAORGHSA-N (1s)-1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-3h-2-benzofuran-5-carbonitrile;oxalic acid Chemical compound OC(=O)C(O)=O.C1([C@]2(C3=CC=C(C=C3CO2)C#N)CCCN(C)C)=CC=C(F)C=C1 KTGRHKOEFSJQNS-BDQAORGHSA-N 0.000 description 1
- 208000007848 Alcoholism Diseases 0.000 description 1
- 206010003497 Asphyxia Diseases 0.000 description 1
- 206010008479 Chest Pain Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 208000020401 Depressive disease Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 206010066392 Fear of death Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 208000033830 Hot Flashes Diseases 0.000 description 1
- 206010060800 Hot flush Diseases 0.000 description 1
- 208000008454 Hyperhidrosis Diseases 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 201000007930 alcohol dependence Diseases 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000002426 anti-panic effect Effects 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 238000011461 current therapy Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 238000009837 dry grinding Methods 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 229960005086 escitalopram oxalate Drugs 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000012442 inert solvent Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 208000035824 paresthesia Diseases 0.000 description 1
- 208000022821 personality disease Diseases 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 208000019899 phobic disease Diseases 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 1
- 239000003762 serotonin receptor affecting agent Substances 0.000 description 1
- 229940126570 serotonin reuptake inhibitor Drugs 0.000 description 1
- 239000003772 serotonin uptake inhibitor Substances 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 238000001238 wet grinding Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Anesthesiology (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Compounds Of Unknown Constitution (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA199900991 | 1999-07-08 | ||
| PCT/DK2000/000377 WO2001003694A1 (en) | 1999-07-08 | 2000-07-07 | Treatment of neurotic disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SK82002A3 true SK82002A3 (en) | 2002-07-02 |
Family
ID=8099796
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SK8-2002A SK82002A3 (en) | 1999-07-08 | 2000-07-07 | Use of the escitalopram and pharmaceutically acceptable salt thereof |
Country Status (38)
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR021155A1 (es) * | 1999-07-08 | 2002-06-12 | Lundbeck & Co As H | Tratamiento de desordenes neuroticos |
| GB0005477D0 (en) | 2000-03-07 | 2000-04-26 | Resolution Chemicals Limited | Process for the preparation of citalopram |
| WO2002008216A1 (en) | 2000-07-21 | 2002-01-31 | H. Lundbeck A/S | Novel compounds and their use as glycine transport inhibitors |
| EA200301195A1 (ru) * | 2001-05-01 | 2004-04-29 | Х. Лундбекк А/С | Применение энантиомерно чистого эсциталопрама |
| BR0206164A (pt) | 2001-07-31 | 2003-10-28 | Lundbeck & Co As H | Partìculas cristalinas de oxalato de escitalopram, método para a produção de partìculas cristalinas de oxalato de escitalopram, e, forma de dosagem unitária sólida |
| WO2004004721A1 (en) * | 2002-07-08 | 2004-01-15 | University Of Florida | Use of ssri inhibitors to prevent or ameliorate trauma-related psychological disorders |
| UA80170C2 (en) * | 2002-12-23 | 2007-08-27 | Lundbeck & Co As H | Escitalopram hydrobromide |
| US20050137255A1 (en) * | 2002-12-23 | 2005-06-23 | H. Lundbeck A/S | Crystalline escitalopram hydrobromide and methods for preparing the same |
| US20050154052A1 (en) * | 2003-03-24 | 2005-07-14 | Hetero Drugs Limited | Novel crystalline forms of (s)-citalopram oxalate |
| US20090093461A1 (en) * | 2003-07-02 | 2009-04-09 | Astrazeneca Ab | Methods of Treating Anxiety and Mood Disorders |
| US7884096B2 (en) * | 2003-12-02 | 2011-02-08 | Pharmaneuroboost N.V. | Method of treating mental disorders using of D4 and 5-HT2A antagonists, inverse agonists or partial agonists |
| CA2547639A1 (en) * | 2003-12-02 | 2005-06-16 | B&B Beheer Nv | Use of d4 and 5-ht2a antagonists, inverse agonists or partial agonists |
| US7855195B2 (en) * | 2003-12-02 | 2010-12-21 | Pharmaneuroboost N.V. | Method of treating mental disorders using D4 and 5-HT2A antagonists, inverse agonists or partial agonists |
| EP1954257A4 (en) | 2005-10-14 | 2009-05-20 | Lundbeck & Co As H | METHOD FOR TREATING DISORDERS OF THE CENTRAL NERVOUS SYSTEM WITH A LOW-DOSED COMBINATION OF ESCITALOPRAM AND BUPROPION |
| US20070134322A1 (en) * | 2005-12-14 | 2007-06-14 | Forest Laboratories, Inc. | Modified and pulsatile release pharmaceutical formulations of escitalopram |
| FR2912057B1 (fr) * | 2007-02-07 | 2009-04-17 | Sanofi Aventis Sa | Composition pharmaceutique contenant en association le saredutant et un inhibiteur selectif de la recapture de la serotonine ou un inhibiteur de la recapture de la serotonine/norepinephrine |
| TW200817003A (en) * | 2006-07-31 | 2008-04-16 | Sanofi Aventis | Pharmaceutical composition comprising, in combination, saredutant and a selective serotonin peuptake inhibitor or a serotonin/norepinephrine reuptake inhibitor |
Family Cites Families (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1143702A (https=) | 1965-03-18 | |||
| GB1526331A (en) | 1976-01-14 | 1978-09-27 | Kefalas As | Phthalanes |
| US4439545A (en) | 1981-11-19 | 1984-03-27 | Societe D "Expansion Scientifique "Expansia" | Acrylic copolymers of N-acryloylpolymethyleneimines or N-acryloyldialkylamides, N,N'-acryloyldiaminoalcanes and N-acryloylaminoacids (or esters) their preparation and use as cation exchangers |
| GB8419963D0 (en) | 1984-08-06 | 1984-09-12 | Lundbeck & Co As H | Intermediate compound and method |
| GB8607313D0 (en) * | 1986-03-25 | 1986-04-30 | Ici Plc | Pharmaceutical compositions |
| GB8814057D0 (en) | 1988-06-14 | 1988-07-20 | Lundbeck & Co As H | New enantiomers & their isolation |
| US4902710A (en) | 1988-12-14 | 1990-02-20 | Eli Lilly And Company | Serotonin and norepinephrine uptake inhibitors |
| US5114976A (en) | 1989-01-06 | 1992-05-19 | Norden Michael J | Method for treating certain psychiatric disorders and certain psychiatric symptoms |
| US4962128A (en) | 1989-11-02 | 1990-10-09 | Pfizer Inc. | Method of treating anxiety-related disorders using sertraline |
| DK213290D0 (da) | 1990-09-06 | 1990-09-06 | Lundbeck & Co As H | Treatment of cerebrovascular disorders |
| US5296507A (en) * | 1990-09-06 | 1994-03-22 | H.Lundbeck A/S | Treatment of cerbrovascular disorders |
| US5708035A (en) | 1991-02-04 | 1998-01-13 | Sepracor Inc. | Methods of use and compositions of R(-) fluoxetine |
| WO1992018005A1 (en) | 1991-04-16 | 1992-10-29 | National Institutes Of Health | Method of treating trichotillomania and onychophagia |
| ATE244563T1 (de) | 1991-11-15 | 2003-07-15 | Sepracor Inc | Verwendung von reinem fluoxetin-s(+)-isomer für die herstellung eines medikements gegen migräne |
| EP0714663A3 (en) * | 1994-11-28 | 1997-01-15 | Lilly Co Eli | Potentiation of drug responses by serotonin 1A receptor antagonists |
| US5627196A (en) * | 1995-01-17 | 1997-05-06 | Eli Lilly And Company | Compounds having effects on serotonin-related systems |
| WO1996024353A1 (en) * | 1995-02-10 | 1996-08-15 | Eli Lilly And Company | Methods of treating or preventing psychiatric disorders |
| US5554383A (en) | 1995-04-06 | 1996-09-10 | Trustees Of Tufts College | Veterinary method for clinically modifying the behavior of dogs exhibiting canine affective aggression |
| SE9501567D0 (sv) | 1995-04-27 | 1995-04-27 | Astra Ab | A new combination |
| ATE192042T1 (de) | 1995-08-16 | 2000-05-15 | Lilly Co Eli | Potenzierung von serotonin-wirkstoffresponz |
| US5846982A (en) * | 1996-06-14 | 1998-12-08 | Eli Lilly And Company | Inhibition of serotonin reuptake |
| US5912256A (en) * | 1996-06-20 | 1999-06-15 | Eli Lilly And Company | Compounds having effects on serotonin-related systems |
| US5747494A (en) * | 1996-06-28 | 1998-05-05 | U C B S.A. | Pharmaceutical compositions for the treatment of depressive disorders |
| US5958429A (en) | 1996-08-16 | 1999-09-28 | Eli Lilly And Company | Potentiation of serotonin response |
| ZA977967B (en) | 1996-09-23 | 1999-03-04 | Lilly Co Eli | Combination therapy for treatment of psychoses |
| US5776969A (en) * | 1997-02-27 | 1998-07-07 | Eli Lilly And Company | Treatment of sleep disorders |
| US6069177A (en) | 1997-07-08 | 2000-05-30 | The Hong Kong University Of Science And Technology | 3-Hydroxy-propanamine derived neuronal reuptake inhibitors |
| SE9703375D0 (sv) | 1997-09-18 | 1997-09-18 | Astra Ab | A new combination |
| SE9703379D0 (sv) * | 1997-09-18 | 1997-09-18 | Astra Ab | New compounds |
| EP1042310B1 (en) * | 1997-11-11 | 2002-07-31 | H. Lundbeck A/S | Method for the preparation of citalopram |
| ATE228119T1 (de) * | 1998-04-15 | 2002-12-15 | Pfizer Prod Inc | Heterocyclische carboxamide |
| EP1100501A4 (en) * | 1998-06-30 | 2002-12-04 | Lilly Co Eli | PYRROLIDINE AND PYRROLIDINE DERIVATIVES INFLUENTING THE SYSTEMS ASSOCIATED WITH SEROTONIN |
| AU771252B2 (en) | 1998-07-13 | 2004-03-18 | Nps Pharmaceuticals, Inc. | Methods and compounds for treating depression and other disorders |
| US6579899B1 (en) | 1998-07-16 | 2003-06-17 | Massachusetts Institute Of Technology | Composition for treatment of stress |
| JP2002520353A (ja) | 1998-07-16 | 2002-07-09 | マサチューセッツ インスティテュート オブ テクノロジー | ストレスの処置のための組成物 |
| US6150376A (en) * | 1998-08-05 | 2000-11-21 | Georgetown University | Bi- and tri-cyclic aza compounds and their uses |
| SE9803157D0 (sv) | 1998-09-16 | 1998-09-16 | Astra Ab | A new composition |
| SE9803158D0 (sv) * | 1998-09-16 | 1998-09-16 | Astra Ab | A new composition |
| CA2291134C (en) * | 1998-10-20 | 2006-05-23 | H. Lundbeck A/S | Method for the preparation of citalopram |
| AR021509A1 (es) * | 1998-12-08 | 2002-07-24 | Lundbeck & Co As H | Derivados de benzofurano, su preparacion y uso |
| AU759716B2 (en) * | 1999-04-14 | 2003-04-17 | H. Lundbeck A/S | Method for the preparation of citalopram |
| AR021155A1 (es) * | 1999-07-08 | 2002-06-12 | Lundbeck & Co As H | Tratamiento de desordenes neuroticos |
| US6333357B1 (en) | 1999-11-05 | 2001-12-25 | Be Able, Llc | Behavior chemotherapy |
| UA77650C2 (en) | 1999-12-06 | 2007-01-15 | Lundbeck & Co As H | Use of serotonin reuptake inhibitor in combination with deramcyclane |
| GB2357762B (en) * | 2000-03-13 | 2002-01-30 | Lundbeck & Co As H | Crystalline base of citalopram |
| WO2001080845A2 (en) | 2000-04-24 | 2001-11-01 | Aryx Therapeutics | (2-aminoethyl) oxime derivatives for the treatment of depression |
| JP2002361405A (ja) * | 2000-09-25 | 2002-12-18 | Showa Denko Kk | 熱交換器の製造方法 |
| EA200301195A1 (ru) * | 2001-05-01 | 2004-04-29 | Х. Лундбекк А/С | Применение энантиомерно чистого эсциталопрама |
-
2000
- 2000-07-06 AR ARP000103442A patent/AR021155A1/es unknown
- 2000-07-07 AU AU58061/00A patent/AU782514B2/en not_active Expired
- 2000-07-07 UA UA2001128286A patent/UA77645C2/uk unknown
- 2000-07-07 IL IL14613100A patent/IL146131A0/xx unknown
- 2000-07-07 EP EP04007522A patent/EP1440691A3/en not_active Withdrawn
- 2000-07-07 SK SK8-2002A patent/SK82002A3/sk not_active Application Discontinuation
- 2000-07-07 HK HK03100231.6A patent/HK1048069B/zh not_active IP Right Cessation
- 2000-07-07 KR KR1020017016006A patent/KR100604176B1/ko not_active Ceased
- 2000-07-07 SI SI200030910T patent/SI1200081T1/sl unknown
- 2000-07-07 TR TR2004/02275T patent/TR200402275T2/xx unknown
- 2000-07-07 MY MYPI20003122A patent/MY143278A/en unknown
- 2000-07-07 MX MXPA01011626A patent/MXPA01011626A/es not_active Application Discontinuation
- 2000-07-07 CZ CZ200270A patent/CZ200270A3/cs unknown
- 2000-07-07 AT AT00943692T patent/ATE339955T1/de active
- 2000-07-07 CN CNB008100292A patent/CN1198610C/zh not_active Expired - Lifetime
- 2000-07-07 DK DK00943692T patent/DK1200081T3/da active
- 2000-07-07 DE DE60030861T patent/DE60030861T2/de not_active Expired - Lifetime
- 2000-07-07 EP EP04007520A patent/EP1440689A3/en not_active Withdrawn
- 2000-07-07 CO CO00051031A patent/CO5190674A1/es not_active Application Discontinuation
- 2000-07-07 PL PL00352030A patent/PL352030A1/xx not_active Application Discontinuation
- 2000-07-07 WO PCT/DK2000/000377 patent/WO2001003694A1/en not_active Ceased
- 2000-07-07 HU HU0201791A patent/HUP0201791A3/hu unknown
- 2000-07-07 JP JP2001508974A patent/JP4773011B2/ja not_active Expired - Lifetime
- 2000-07-07 HR HR20010820A patent/HRP20010820A2/hr not_active Application Discontinuation
- 2000-07-07 CA CA2687396A patent/CA2687396A1/en not_active Abandoned
- 2000-07-07 BR BR0011578-9A patent/BR0011578A/pt active Search and Examination
- 2000-07-07 TR TR2002/00014T patent/TR200200014T2/xx unknown
- 2000-07-07 ME MEP-25/08A patent/MEP2508A/xx unknown
- 2000-07-07 PT PT00943692T patent/PT1200081E/pt unknown
- 2000-07-07 TR TR2004/02276T patent/TR200402276T2/xx unknown
- 2000-07-07 EP EP00943692A patent/EP1200081B1/en not_active Revoked
- 2000-07-07 ME MEP-2008-25A patent/ME00032B/me unknown
- 2000-07-07 CA CA2687392A patent/CA2687392A1/en not_active Abandoned
- 2000-07-07 YU YU78701A patent/YU78701A/sh unknown
- 2000-07-07 EP EP04007521A patent/EP1440690A3/en not_active Withdrawn
- 2000-07-07 ES ES00943692T patent/ES2272298T3/es not_active Expired - Lifetime
- 2000-07-07 EA EA200200137A patent/EA006555B1/ru not_active IP Right Cessation
- 2000-07-07 CA CA2687394A patent/CA2687394A1/en not_active Abandoned
- 2000-07-07 TR TR2004/02277T patent/TR200402277T2/xx unknown
- 2000-07-07 CA CA002373757A patent/CA2373757C/en not_active Expired - Lifetime
- 2000-07-28 TW TW089115110A patent/TWI232101B/zh not_active IP Right Cessation
-
2001
- 2001-10-23 IL IL146131A patent/IL146131A/en active IP Right Grant
- 2001-10-26 ZA ZA200108856A patent/ZA200108856B/xx unknown
- 2001-10-30 IS IS6137A patent/IS6137A/is unknown
- 2001-12-12 US US10/021,126 patent/US7271194B2/en not_active Expired - Lifetime
-
2002
- 2002-01-04 BG BG106279A patent/BG106279A/bg unknown
- 2002-01-04 BG BG11046709A patent/BG110467A/bg unknown
- 2002-01-04 BG BG11046609A patent/BG110466A/bg unknown
- 2002-01-04 BG BG11046809A patent/BG110468A/bg unknown
- 2002-01-07 NO NO20020062A patent/NO329021B1/no not_active IP Right Cessation
-
2003
- 2003-08-07 US US10/637,821 patent/US20040029957A1/en not_active Abandoned
- 2003-08-07 US US10/637,820 patent/US7265151B2/en not_active Expired - Lifetime
- 2003-08-07 US US10/637,822 patent/US20040029958A1/en not_active Abandoned
- 2003-08-20 US US10/644,143 patent/US6960613B2/en not_active Expired - Lifetime
-
2005
- 2005-06-20 AU AU2005202686A patent/AU2005202686B2/en not_active Expired
- 2005-06-20 AU AU2005202684A patent/AU2005202684B2/en not_active Ceased
- 2005-06-20 AU AU2005202685A patent/AU2005202685B2/en not_active Ceased
- 2005-08-09 IL IL170193A patent/IL170193A/en unknown
- 2005-08-09 IL IL170194A patent/IL170194A/en unknown
- 2005-08-09 IL IL170192A patent/IL170192A/en unknown
-
2006
- 2006-11-27 CY CY20061101706T patent/CY1105806T1/el unknown
-
2007
- 2007-08-10 US US11/837,317 patent/US20070276035A1/en not_active Abandoned
-
2008
- 2008-12-24 AU AU2008264188A patent/AU2008264188A1/en not_active Withdrawn
- 2008-12-24 AU AU2008264182A patent/AU2008264182A1/en not_active Withdrawn
- 2008-12-30 CL CL2008003941A patent/CL2008003941A1/es unknown
- 2008-12-30 CL CL2008003938A patent/CL2008003938A1/es unknown
- 2008-12-30 CL CL2008003939A patent/CL2008003939A1/es unknown
-
2010
- 2010-03-10 NO NO20100335A patent/NO20100335L/no not_active Application Discontinuation
- 2010-03-10 NO NO20100334A patent/NO20100334L/no not_active Application Discontinuation
- 2010-03-10 NO NO20100333A patent/NO20100333L/no not_active Application Discontinuation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20070276035A1 (en) | Treatment of neurotic disorders | |
| EA008373B1 (ru) | Применение эсциталопрама для лечения расстройства, связанного с посттравматическим стрессом |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC9A | Refused patent application |